# A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia

> **NCT04925206** · PHASE1 · TERMINATED · sponsor: **EdiGene (GuangZhou) Inc.** · enrollment: 8 (actual)

## Conditions studied

- Transfusion Dependent Beta-Thalassaemia

## Interventions

- **BIOLOGICAL:** ET-01

## Key facts

- **NCT ID:** NCT04925206
- **Lead sponsor:** EdiGene (GuangZhou) Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2021-08-17
- **Primary completion:** 2024-01-30
- **Final completion:** 2025-03-12
- **Target enrollment:** 8 (ACTUAL)
- **Why stopped:** Development plan change
- **Last updated:** 2025-03-30


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04925206

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04925206, "A Safety and Efficacy Study Evaluating ET-01 in Subjects with Transfusion Dependent Β-Thalassaemia". Retrieved via AI Analytics 2026-06-05 from https://api.ai-analytics.org/clinical/NCT04925206. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*